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Development of a Lateral Flow Recombinase Polymerase Assay for the 1 diagnosis of Schistosoma mansoni infections 2
Introduction 35
Schistosomiasis is a neglected tropical disease (NTD) second only to malaria in 36 infection rates [1] with 230 million people estimated to be infected worldwide [2, 3] . It is 37 endemic in Africa, Asia, the Middle East and parts of South America, however the greatest 38 burden of disease is found in sub-Saharan Africa where S. haematobium (causing urogenital 39 schistosomiasis) and S. mansoni (causing intestinal schistosomiasis) cause 90% of global 40 infections resulting in an estimated mortality rate of around 200,000 per year [4] . Infection 41 occurs when larval stages of the parasite are shed from the specific fresh water snails and 42 enter through the human skin via water contact. These larval forms mature in the liver and 43 then migrate to either the mesenteric veins (S. mansoni) or to the perivesicular veins (S. 44 haematobium) where adult worms exist as a reproductive pair and produce many 45 thousands of eggs per day [2] . The World Health Organization (WHO) has targeted 46 schistosomiasis for elimination as a public health problem (defined as reducing prevalence 47 of heavy-intensity infection to below 1%) in all endemic countries with a halt in transmission 48 in most of these countries by 2025 [5, 6] . This is to be achieved principally through mass 49 drug administration (MDA) of oral praziquantel (PZQ) to kill adult worms [5] but will also 50 require sensitive diagnostics to be able to identify low intensity infections, and also to set 51 effective treatment intervals. The current standard diagnostic test for S. mansoni infection 52 involves taking a double smear of a single stool sample for microscopic detection of 53 schistosome eggs [7, 8] . This is not only time-consuming, but lacks sensitivity particularly in 54 low-intensity infections [7] [8] [9] [10] [11] [12] [13] [14] [15] , leading to an under-estimation of disease prevalence. It is 55 probable therefore that many infections are being missed using current diagnostic methods, 56 and elimination goals are unlikely to be achieved unless a more sensitive, quick, easy to 57 perform and cost-effective method of detection is developed. 58
Molecular diagnostics and molecular technologies are rapidly advancing and offer 59 greater sensitivities and specificities over existing disease diagnostics. For the detection and 60 quantification of Schistosoma-specific DNA in clinical samples, a number of molecular 61 techniques and range of molecular targets have been put into practice [16] [17] [18] . Polymerase 62 M A N U S C R I P T Primers were screened using the TwistAmp TM Basic kit to determine the best primer 111 pairs according to product yield using the TwistAmp TM Basic kit reagents. To prevent cross 112 contamination, preparation of all RPA reactions was carried out in a pre-PCR room under 113 extraction hoods, and all reagents were left under UV light before and after each batch of 114 reactions was run. There were eight possible primer pairs to be tested; six ITS pair 115 combinations covering a 267bp region, and two 28S primer pair combinations covering a 116 327bp region. All primer screening was done using 1ng of S. mansoni genomic DNA. 117
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Reactions were set-up following the TwistDx TM Basic RPA protocol with each reaction 118 containing 29.5µl rehydration buffer, 2.4µl of each forward and reverse primer (10pmol), 119 12.2µl dH 2 0, and 1µl of S. mansoni genomic DNA for each reaction mix. The RPA pellets 120 were first decanted into 0.2ml PCR tubes for easier handling, the reaction mix was then 121 added, vortexed and spun down. 2.5µl of magnesium acetate was added to each lid making 122 a total reaction volume of 50µl and a magnetic bead was dispensed into each tube for 123 magnetic mixing. Tubes were centrifuged and immediately placed into the Twirla 
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
using the standard 28S LF-RPA protocol and the reactions were performed in the Twirla 219 device with magnetic mixing at 40°C for 20 minutes. Amplicon detection was performed 220 using the PCRD reaction strips as described previously. The limit of detection was tested 221 multiple times to assess robustness of the assay. 222
Results 223

ITS and 28S RPA primers and probes 224
Sequences for all ITS and 28S primers and probes are shown in Table 1 
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(127bp*), 3. 59F + 192R (133bp*) and one 28S primer pair (353F + 647R (294bp*)), were 237 selected for further optimisation based on the smaller amplicon lengths produced and 238 strong band signal intensity (Figure 1) . A shorter amplicon is more desirable as it will equate 239 to a faster amplification rate and generates fewer primer 'artefacts', providing greater 240 sensitivity [32] . Hyperladder IV. *These primer pairs were chosen for further optimization and LF RPA 254 development. 255
Lateral Flow (LF) RPA development 256
Due to the high cost of the internal LF probes only a single ITS and 28S probe were designed 257 and tested. 258
ITS LF-RPA assays 259
The ITS LF-RPA reactions were hampered by false positive results with all the primer probe 260 combinations tested. It was suspected that false positives might be caused by a possible 261 overlap of reverse primer with the probe due to them only being separated by just one 262 base. We substituted the biotinylated ITS 312R primer in place of the ITS 192R primer in the 263 reactions to increase reverse primer-probe gap to 122 bases, however this was unsuccessful 264 in preventing false positives occurring (Figure 2a) . The ITS LF-RPA amplification products 265 were purified and run on agarose gel to visualise any non-specific DNA products that might 266 be causing the anomaly. It was evident that additional non-specific bands slightly smaller 267 A B 
28S LF-RPA assays 300
The 28S primer / probe combinations did not produce false positive results thus the 28S 301 primer pair that gave the shortest amplicon of 294 bases (28S 353F/28S 647R) was used in 302 all 28S LF-RPA parameter testing assays (Figure 4) . 
Sensitivity testing 345
The ITS LF-RPA assay was tested on serial dilutions of S. mansoni genomic DNA. 346
Unfortunately at lower concentrations inconsistent results were obtained from reactions on 347 the same concentration of DNA and so the limit of detection could not be evaluated further. 348
For the 28S LF-RPA assay consistent results were obtained from replicate reactions and the 349 28S LF-RPA assay limit of sensitivity was 10pg of DNA (Supplementary File Figure 10) . 350 351
Analytical limit of Detection of the 28S LF-RPA assay 352
The analytical lower limit of detection for the 28S LF-RPA assay was 10 2 copies of DNA 353 (Supplementary File Figure 11 ). 354 355
Specificity with other important schistosome species 356
The ITS LF-RPA assay proved to be not specific to S. mansoni and was also able to amplify S. 357 haematobium and S. bovis DNA (Supplementary File Figure 12A ) whereas the 28S LF-RPA 358 assay proved to be more specific to S. mansoni but was still able to amplify S. haematobium 359 and S. bovis DNA but at a lower sensitivity and with faint detection lines observed on the 360 PCRD strips (Supplementary File Figure 12B ).
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Discussion 362
A diagnostic test that is both sensitive and specific is of paramount importance to 363 successfully monitor schistosomiasis transmission, particularly in low endemic areas. 364
Inaccuracies in prevalence data due to lack of sensitivity of diagnostics could lead to a 365 premature reduction/withdrawal of MDA, leading to a rapid resurgence of transmission and 366 disease. Alternatively over-prescription of the drugs caused by a lack of diagnostic specificity 367 causes wastage of medicine, insufficient supply of PZQ, systematic non-compliance and 368 potentially could lead to the development of PZQ resistance. Ultimately this will prevent 369 WHO elimination targets from being reached [5] . M A N U S C R I P T
